Kelly Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 20-12-2024
- Paid Up Capital ₹ 0.10 M
as on 20-12-2024
- Company Age 6 Year, 8 Months
- Last Filing with ROC 31 Mar 2024
- Revenue 89.86%
(FY 2022)
- Profit 48.22%
(FY 2022)
- Ebitda 27.94%
(FY 2022)
- Net Worth 25.29%
(FY 2022)
- Total Assets -18.15%
(FY 2022)
About Kelly Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Abdul Kadir and Niti Choubey serve as directors at the Company.
- CIN/LLPIN
U51909DL2018PTC333086
- Company No.
333086
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
25 Apr 2018
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
Delhi, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Kelly Pharmaceuticals Private Limited offer?
Kelly Pharmaceuticals Private Limited offers a wide range of products and services, including Nutraceuticals & Dietary Supplements, Mineral Supplement, Vitamin Tablets & Capsules, Anti Infective Drugs & Medicines, Antibiotic Tablets, Capsule & Syrup, Digestive System Drugs & Medicines, Antacid Drugs.
Who are the key members and board of directors at Kelly Pharmaceuticals?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Niti Choubey  | Managing Director | 25-Apr-2018 | Current |
Board Members(1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Abdul Kadir | Director | 02-Feb-2022 | Current |
Financial Performance of Kelly Pharmaceuticals.
Kelly Pharmaceuticals Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 89.86% increase. The company also saw a substantial improvement in profitability, with a 48.22% increase in profit. The company's net worth Soared by an impressive increase of 25.29%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Kelly Pharmaceuticals?
In 2021, Kelly Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Kelly Pharmaceuticals?
Unlock and access historical data on people associated with Kelly Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Kelly Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Kelly Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
